Allergan has signed a deal for the acquisition of Oculeve, an Irish medical device company that is developing treatments for the dry eye disease. It will pay $125 million upfront and more depending on revenues from Oculeve's OD-01 development program. The transaction is expected to close in the third quarter of 2015, depending on regulatory approval.

Topics